IP Library Granted Patent US 9,220,736
Granted Patent B2
US 9,220,736 · App. 11/985,617 · Granted Dec 29, 2015

Methods for the dietary management of irritable bowel syndrome and carbohydrate malabsorption

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,220,736
App. No.
11/985,617
Granted
Dec 29, 2015
Kind
B2
Abstract

The invention relates generally to digestive disorders, and in particular to methods for treating irritable bowel syndrome by increasing carbohydrate absorption by administering a composition containing a Bacillus coagulans bacterium.

Claims (21)

1. A method of reducing a symptom of irritable bowel syndrome, comprising the steps of: identifying a subject having a symptom of irritable bowel syndrome; and providing a composition comprising an effective amount of viable Bacillus coagulans bacterial spores to said subject, wherein said bacterial spores are from Bacillus coagulans selected from the group consisting of GBI-20 (ATCC Designation Number PTA-6085), GBI-30 (ATCC Designation Number PTA-6086), and GBI-40 (ATCC Designation Number PTA-6087), wherein said composition comprising Bacillus coagulans is administered orally, and wherein a symptom of irritable bowel syndrome in said subject is reduced following said administration.

2. The method of claim 1 , wherein said composition further comprises a supplementary enzyme, wherein said enzyme is selected from the group consisting of a lactase, a fructase, a lipase, an amylase and a protease.

3. The method of claim 1 , wherein said symptom is gas or bloating.

4. The method of claim 1 , wherein said composition further comprises an anti-gas agent.

5. The method of claim 4 , wherein said anti-gas agent is selected from the group of α-galactosidase enzyme, simethicone, calcium carbonate, aluminum hydroxide and magnesium hydroxide.

6. The method of claim 1 , wherein said composition comprises about 1×10 8 to about 1×10 10 Bacillus coagulans bacterial spores.

7. A method of reducing a symptom of irritable bowel syndrome (IBS), comprising identifying a subject suffering from irritable bowel syndrome, and orally administering to said subject a composition comprising an effective IBS-inhibiting amount of Bacillus coagulans bacterial spores prior to or concomitant with the onset of one or more IBS symptoms, wherein said bacterial spores are from Bacillus coagulans selected from the group consisting of GBI-20 (ATCC Designation Number PTA-6085), GBI-30 (ATCC Designation Number PTA-6086), and GBI-40 (ATCC Designation Number PTA-6087), wherein said composition comprising Bacillus coagulans is administered orally, and wherein a symptom of irritable bowel syndrome in said subject is reduced following said administration.

8. The method of claim 7 , wherein said composition further comprises a supplementary enzyme, wherein said enzyme is selected from the group consisting of a lactase, a fructase, a lipase, an amylase, and a protease.

9. The method of claim 7 , wherein said composition comprises about 1×10 8 to about 1×10 10 Bacillus coagulans spores.

10. The method of claim 1 , wherein the subject is a human.

11. The method of claim 7 , wherein the subject is a human.

12. The method of claim 1 , wherein said Bacillus coagulans is GBI-30 strain (ATCC Designation Number PTA-6086).

13. The method of claim 7 , wherein said Bacillus coagulans is GBI-30 strain (ATCC Designation Number PTA-6086).

14. A method of claim 1 , wherein said composition comprises a ratio of Bacillus coagulans bacterial spores to vegetative cells of approximately 80:20.

15. The method of claim 7 , wherein said composition comprises a ratio of Bacillus coagulans bacterial spores to vegetative cells of approximately 80:20.

16. The method of claim 1 , wherein said composition comprises about 1×10 4 to about 1×10 12 Bacillus coagulans bacterial spores.

17. The method of claim 7 , wherein said composition comprises about 1×10 4 to about 1×10 12 Bacillus coagulans bacterial spores.

18. The method of claim 1 , wherein said composition comprises about 1×10 6 to about 1×10 11 Bacillus coagulans bacterial spores.

19. The method of claim 1 , wherein said composition comprises about 8.0×10 8 Bacillus coagulans bacterial spores.

20. The method of claim 7 , wherein said composition comprises about 1×10 6 to about 1×10 11 Bacillus coagulans bacterial spores.

21. The method of claim 7 , wherein said composition comprises about 8.0×10 8 Bacillus coagulans bacterial spores.

Assignments (5)
RELEASE OF SECURITY INTEREST Recorded Sep 12, 2017
From: SILICON VALLEY BANK
To: GANEDEN BIOTECH, INC.
Reel/Frame 043822/0897 →
SECURITY AGREEMENT Recorded Oct 10, 2012
From: GANEDEN BIOTECH, INC.
To: SILICON VALLEY BANK
Reel/Frame 029103/0202 →
LICENSE Recorded Jul 19, 2011
From: GANEDEN BIOTECH, INC.
To: SCHIFF NUTRITION GROUP, INC.
Reel/Frame 026616/0128 →
SECURITY AGREEMENT Recorded Jul 19, 2011
From: GANEDEN BIOTECH, INC.
To: SCHIFF NUTRITION GROUP, INC.
Reel/Frame 026616/0950 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 15, 2010
From: FARMER, SEAN; LEFKOWITZ, ANDREW R.
To: GANEDEN BIOTECH, INC.
Reel/Frame 025144/0497 →